2297 related articles for article (PubMed ID: 24139829)
41. Guideline recommendations on the use of allergen immunotherapy in house dust mite allergy: Time for a change?
Calderón MA; Bousquet J; Canonica GW; Cardell LO; Fernandez de Rojas DH; Kleine-Tebbe J; Demoly P
J Allergy Clin Immunol; 2017 Jul; 140(1):41-52. PubMed ID: 28526624
[TBL] [Abstract][Full Text] [Related]
42. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
[TBL] [Abstract][Full Text] [Related]
43. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective?
Nelson HS
J Allergy Clin Immunol Pract; 2014; 2(2):144-9; quiz 150-1. PubMed ID: 24607040
[TBL] [Abstract][Full Text] [Related]
44. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting.
Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M
Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466
[TBL] [Abstract][Full Text] [Related]
45. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
Hesse L; Nawijn MC
Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of subcutaneous house dust mite immunotherapy in patients with moderate to severe allergic rhinitis.
Valero A; Ibáñez-Echevarría E; Vidal C; Raducan I; Castelló Carrascosa JV; Sánchez-López J
Immunotherapy; 2022 Jun; 14(9):683-694. PubMed ID: 35465692
[TBL] [Abstract][Full Text] [Related]
47. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
[TBL] [Abstract][Full Text] [Related]
48. Bronchial allergen provocation: a useful method to assess the efficacy of specific immunotherapy in children.
Rosewich M; Arendt S; El Moussaoui S; Schulze J; Schubert R; Zielen S
Pediatr Allergy Immunol; 2013 Aug; 24(5):434-40. PubMed ID: 23578317
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
[TBL] [Abstract][Full Text] [Related]
50. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
[TBL] [Abstract][Full Text] [Related]
51. Clinical and cytokine responses to house dust mite sublingual immunotherapy.
Potter PC; Baker S; Fenemore B; Nurse B
Ann Allergy Asthma Immunol; 2015 Apr; 114(4):327-34. PubMed ID: 25661658
[TBL] [Abstract][Full Text] [Related]
52. Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis.
Jordakieva G; Kundi M; Lemell P; Zieglmayer R; Zieglmayer P; Godnic-Cvar J; Jensen-Jarolim E
Sci Rep; 2017 May; 7(1):2555. PubMed ID: 28566688
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of sublingual versus subcutaneous immunotherapy in children with allergic rhinitis: a systematic review and meta-analysis.
Yang J; Lei S
Front Immunol; 2023; 14():1274241. PubMed ID: 38162647
[TBL] [Abstract][Full Text] [Related]
54. A randomized, double-blind, placebo controlled trial of sublingual immunotherapy with house-dust mite extract for allergic rhinitis.
Guo Y; Li Y; Wang D; Liu Q; Liu Z; Hu L
Am J Rhinol Allergy; 2017 Jul; 31(4):42-47. PubMed ID: 28716168
[TBL] [Abstract][Full Text] [Related]
55. Sublingual Versus Subcutaneous Immunotherapy as regards Efficacy and Safety in Respiratory Allergic Patients.
Atta AH; Amer RM; Mesbah AE; Khater MW
Egypt J Immunol; 2019 Jul; 26(2):65-78. PubMed ID: 31926496
[TBL] [Abstract][Full Text] [Related]
56. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma.
Blumberga G; Groes L; Dahl R
Allergy; 2011 Feb; 66(2):178-85. PubMed ID: 20883456
[TBL] [Abstract][Full Text] [Related]
57. [Efficacy and safety of sublingual immunotherapy with house dust mite extract in poly allergen sensitized children with allergic rhinitis].
Zhou L; Wang J; Chen Y; Luo R; Tao J; Nie M; Liu B; Li Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Oct; 26(20):913-6. PubMed ID: 23272490
[TBL] [Abstract][Full Text] [Related]
58. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children.
Corzo JL; Carrillo T; Pedemonte C; Plaza Martin AM; Martín Hurtado S; Dige E; Calderon MA
J Investig Allergol Clin Immunol; 2014; 24(3):154-61. PubMed ID: 25011352
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo-controlled trials.
Tao L; Shi B; Shi G; Wan H
Clin Respir J; 2014 Apr; 8(2):192-205. PubMed ID: 24118881
[TBL] [Abstract][Full Text] [Related]
60. Semi-depot house-dust mite allergen extract for Chinese with allergic rhinitis and asthma.
Li X; Wang X; Lin X; Xu G; Tao Z; Jiang W; Cheng L; Guo Y; Lai H; Shen K
Am J Rhinol Allergy; 2016 May; 30(3):201-8. PubMed ID: 27216351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
